Alnylam Pharmaceuticals price to free cash flow ALNY

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Oct 23, 2026: 37.8×
3-year median: 110×
Against its 3-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
3-year range: 34.6× to 473×
Peer median: 22.5×

Alnylam Pharmaceuticals' price to free cash flow is 37.8× as of Oct 23, 2026.

That is below its 3-year median of 110×, lower than on 97% of days in the last 3 years.

Over that time it ranged from 34.6× in Jul 2026 to 473× in Feb 2024.

The median for 10 biotech stocks of a similar size is 22.5×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	37.8×	34.6×	239×
2025	239×	237×	273×
2024	115×	99.4×	473×

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
ALNYAlnylam Pharmaceuticals	37.8×
UTHRUnited Therapeutics	23.1×
INCYIncyte	12.2×
ONCBeOne Medicines	32.3×
EXELExelixis	13.6×
NBIXNeurocrine Biosciences	16.7×
HALOHalozyme Therapeutics	17.7×
TECHBIO-TECHNE	43.2×
REGNRegeneron Pharmaceuticals	22.0×
RGENRepligen	89.2×
KRYSKrystal Biotech	35.8×
Peer median	22.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.